Accession Number: | 0001439222-21-000053 |
Date: | 2021-05-28 |
Issuer: | AGIOS PHARMACEUTICALS, INC. (AGIO) |
Original Submission Date: |
FOSTER-CHEEK KAYE I
C/O AGIOS PHARMACEUTICALS, INC.
88 SIDNEY STREET
CAMBRIDGE, MA 02139
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-05-28 | M | 1,686 | a | $0.00 | 7,164 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
RESTRICTED STOCK UNITS | 0.0 | 2021-05-28 | deemed execution date | M | 1,686 (d) | common stock 1,686 | $0.00 | 0 | direct |
ID | footnote |
---|---|
f1 | each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. |
f2 | the restricted stock units were granted on may 28, 2020. the shares underlying the stock units will vest in full on may 28, 2021. vested shares will be delivered to the reporting person within three businessdays after such shares become vested. |